Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
NEC Snaps Up Norway’s Bioinformatics Firm
Japanese electronics major NEC said on July 29 that it has acquired Norwegian bioinformatics company OncoImmunity, which specializes in the development of machine-learning based software solutions for cancer immunotherapies, as part of its drive to expand its business into AI-driven…
To read the full story
Related Article
- NEC Harnessing AI Prowess to Pursue Global Players in Cancer Vaccine Race
December 11, 2023
- NEC Ties Up with French Biotech to Develop Neoantigen Vaccines Using AI
May 28, 2019
- NEC Ventures into AI-Based Drug Discovery Biz
December 21, 2016
BUSINESS
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Voyxact PIII Data Confirm Kidney Function Stabilization in IgAN
August 5, 2026
- Perioperative Imfinzi Seen Advancing Gastric Cancer Care: Oncologist
August 5, 2026
- Teijin Still Seeking “Best Owner” for Legacy Drug Portfolio
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…